Hydrogel-Encapsulated Biofilm Inhibitors Abrogate the Cariogenic Activity of Streptococcus Mutans.
Parmanand Ahirwar,Veronika Kozlovskaya,Bhavitavya Nijampatnam,Edwin M. Rojas,Piyasuda Pukkanasut,Daniel Inman,Maksim Dolmat,Anna C. Law,Norbert Schormann,Champion Deivanayagam,Gregory J. Harber,Suzanne M. Michalek,Hui Wu,Eugenia Kharlampieva,Sadanandan E. Velu
DOI: https://doi.org/10.1021/acs.jmedchem.3c00272
IF: 8.039
2023-01-01
Journal of Medicinal Chemistry
Abstract:We designed and synthesized analogues of a previously identified biofilm inhibitor IIIC5 to improve solubility, retain inhibitory activities, and to facilitate encapsulation into pH-responsive hydrogel microparticles. The optimized lead compound HA5 showed improved solubility of 120.09 μg/mL, inhibited Streptococcus mutans biofilm with an IC50 value of 6.42 μM, and did not affect the growth of oral commensal species up to a 15-fold higher concentration. The cocrystal structure of HA5 with GtfB catalytic domain determined at 2.35 Å resolution revealed its active site interactions. The ability of HA5 to inhibit S. mutans Gtfs and to reduce glucan production has been demonstrated. The hydrogel-encapsulated biofilm inhibitor (HEBI), generated by encapsulating HA5 in hydrogel, selectively inhibited S. mutans biofilms like HA5. Treatment of S. mutans-infected rats with HA5 or HEBI resulted in a significant reduction in buccal, sulcal, and proximal dental caries compared to untreated, infected rats.